 Blast Crisis
"Blast Crisis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.
| Descriptor ID |
D001752
|
| MeSH Number(s) |
C04.557.337.539.250.100 C04.697.152.110 C15.378.190.636.370.100 C23.550.727.152.110
|
| Concept/Terms |
Blast Crisis- Blast Crisis
- Blast Crises
- Crises, Blast
- Crisis, Blast
- Blast Phase
- Blast Phases
- Phase, Blast
- Phases, Blast
|
Below are MeSH descriptors whose meaning is more general than "Blast Crisis".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Blast Crisis [C04.557.337.539.250.100]
- Neoplastic Processes [C04.697]
- Cell Transformation, Neoplastic [C04.697.152]
- Blast Crisis [C04.697.152.110]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Blast Crisis [C15.378.190.636.370.100]
- Pathological Conditions, Signs and Symptoms [C23]
- Pathologic Processes [C23.550]
- Neoplastic Processes [C23.550.727]
- Cell Transformation, Neoplastic [C23.550.727.152]
- Blast Crisis [C23.550.727.152.110]
Below are MeSH descriptors whose meaning is more specific than "Blast Crisis".
This graph shows the total number of publications written about "Blast Crisis" by people in this website by year, and whether "Blast Crisis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1990 | 0 | 1 | 1 | | 1993 | 2 | 0 | 2 | | 1995 | 0 | 2 | 2 | | 1996 | 1 | 1 | 2 | | 1999 | 0 | 2 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 0 | 2 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 1 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2018 | 1 | 0 | 1 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Blast Crisis" by people in Profiles.
-
Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, Gerds A, Abboud CN, Kremyanskaya M, Berenzon D, Odenike O, Farnoud N, Krishnan A, Weinberg RS, McGovern E, Salama ME, Najfeld V, Medina-Martinez JS, Arango Ossa JE, Levine MF, Zhou Y, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Hoffman R. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020 10 27; 4(20):5246-5256.
-
Foucar K, Hsi ED, Wang SA, Rogers HJ, Hasserjian RP, Bagg A, George TI, Bassett RL, Peterson LC, Morice WG, Arber DA, Orazi A, Bueso-Ramos CE. Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. Int J Lab Hematol. 2020 Aug; 42(4):418-422.
-
Odenike O. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018 11 29; 132(22):2339-2350.
-
Shao L, Miller S, Keller-Ramey J, Zhang Y, Roulston D. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions. Cancer Genet. 2015 Jul-Aug; 208(7-8):396-403.
-
Boyerinas B, Zafrir M, Yesilkanal AE, Price TT, Hyjek EM, Sipkins DA. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood. 2013 Jun 13; 121(24):4821-31.
-
Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol. 2013 Mar 16; 6:21.
-
Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 02; 121(18):3703-8.
-
Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May; 26(5):959-62.
-
Weinberg OK, Arber DA. Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia. 2010 Nov; 24(11):1844-51.
-
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|